Periodontitis: an inflammatory hub beyond the oral cavity

Long perceived as a strictly localised infectious pathology, periodontitis has now emerged as a major public health challenge, affecting between 35% and 50% of the global adult population. Epidemiological data collected between 2011 and 2020 even show a prevalence peak of 62%, with severe forms affecting 23.6% of adults. In clinical practice, this destruction of the dental supporting apparatus, induced by the biofilm and exacerbated by the host's immune response, can no longer be treated as an isolated clinical entity: it constitutes a true chronic inflammatory focus capable of disseminating pathogenic effects via haematogenous and immunological pathways.

This comprehensive literature review aims to synthesise current evidence regarding the bidirectional associations between periodontitis and a broad spectrum of systemic disorders, notably cardiovascular diseases, diabetes, respiratory diseases, and chronic kidney diseases. The study does not merely list these correlations; it explores the underlying pathophysiological mechanisms, such as bacterial translocation, immune dysregulation, and oxidative stress, in order to provide a solid scientific foundation for interdisciplinary collaboration between dentists and physicians.

The central hypothesis of this work is based on an integrative conceptual model: periodontitis acts as a persistent inflammatory "hub". For the practitioner, the implications are significant, as the study examines how specific oral pathogens (P. gingivalis, T. denticola, A. actinomycetemcomitans) are directly involved in vascular wall inflammation and the acceleration of atherosclerotic lesions. By redefining periodontitis as a systemic pathology of oral origin, this review highlights the importance of preserving periodontal health as a cornerstone of general well-being.

Review methodology

This study is presented as a systematic review aiming to redefine periodontitis no longer as a local infection, but as a chronic inflammatory focus with systemic dissemination. The analysis is based on global epidemiological data collected between 2011 and 2020, concerning a pathology with a prevalence reaching 62% in adults, including 23.6% of severe forms.

For the practitioner, the study structures its clinical assessment on the 2018 consensus report, classifying the disease according to two main axes:

• Staging (Stages I to IV): determining the severity (attachment loss), extent and complexity of management.
• Grading (Grades A, B, C): estimation of the risk of progression and the potential impact on the patient's systemic health.

The analysis protocol investigated the interactions between the dental biofilm (adhesion, maturation and co-aggregation processes) and the host inflammatory cascade. The researchers specifically evaluated four propagation mechanisms: haematogenous bacterial translocation, systemic inflammation, immune dysregulation and oxidative stress pathways.

The study also reports data from experimental models, notably the impact of infection by target pathogens (P. gingivalis, A. actinomycetemcomitans, F. nucleatum) and the effects of angioplasty-induced periodontitis on aortic lipid oxidation. Finally, the analysis integrates the identification of shared genetic susceptibility loci (CDKN2B-AS1, PLG, CAMTA1/VAMP3 and VAMP8), providing a biological basis for the observed correlations between periodontal health and cardiovascular functions.

Periodontitis and Systemic Health: The Figures of a Pathological Connection

Long perceived as a strictly local pathology, periodontitis is now redefined as a chronic inflammatory focus with major systemic repercussions. This review synthesises the current evidence of the impact of periodontal disease on the body, based on precise epidemiological and mechanistic data.

Prevalence and Classification: A Public Health Issue

The figures reported by the study are indisputable: periodontitis affects approximately 35% to 50% of adults worldwide. Between 2011 and 2020, the data show that prevalence reached a peak of 62% in the adult population, with 23.6% of severe forms. For the practitioner, these statistics highlight the omnipresence of the pathology in the practice.

The 2018 classification, used in this study, allows the disease to be stratified to better assess systemic risks:

The Periodontal-Cardiovascular Axis

Periodontitis affects more than 10% of the global population and presents a robust epidemiological association with cardiovascular diseases (CVD). Beyond systemic inflammation, the study highlights a shared genetic predisposition. Specific susceptibility loci have been identified, notably:

• CDKN2B-AS1 (ANRIL)
• PLG
• CAMTA1/VAMP3
• VAMP8

These markers regulate aberrant inflammatory responses, explaining why some of our patients are more susceptible than others to this dual condition.

Focus on Atherosclerosis

This is where the link becomes concrete for the implantologist and the periodontist: oral pathogens have been isolated directly within atheromatous plaques. The study specifically cites:

• Porphyromonas gingivalis
• Aggregatibacter actinomycetemcomitans
• Prevotella intermedia
• Fusobacterium nucleatum
• Treponema denticola

Furthermore, a longitudinal study conducted on Nagasaki Island has established a bidirectional association: initial vascular lesions increase the risk of periodontal progression, while the worsening of periodontitis accelerates the increase in carotid intima-media thickness (IMT).

A notable finding in experimental research: the local application of an anti-inflammatory mediator, Resolvin E1, significantly reduced both arterial plaque formation and periodontal tissue destruction.

The message for the practitioner: When faced with a patient over 55 years of age presenting with signs of periodontitis, controlling the periodontal infection is not just an oral and dental issue; it is an indirect lever to reduce the systemic inflammatory burden and potentially slow the progression of vascular pathologies.

An inflammatory hub at the heart of clinical practice

This study redefines periodontitis no longer as a simple localised infection, but as a true persistent "inflammatory hub". For the practitioner, the presence of oral pathogens such as Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans within atheromatous plaques themselves confirms that the implications of treatment extend far beyond the oral cavity. In the practice, this means that every subgingival debridement potentially contributes to the reduction of a systemic pathological burden.

The results highlight a bidirectional correlation: while periodontitis exacerbates vascular indicators, pre-existing vascular lesions in turn increase the risk of periodontal progression. This is where the interdisciplinary approach becomes concrete: the control of periodontal infection must be integrated into the overall cardiovascular disease prevention strategy, alongside lipid profile management.

However, a caveat is necessary. While the epidemiological association is robust, the study highlights the difficulty of establishing an irrefutable direct causality due to shared risk factors, such as smoking. Despite this mechanistic complexity, the clinical implication remains major: standardised periodontal treatment — including scaling and root planing — constitutes an actionable lever to limit systemic inflammation in our patients at cardiovascular risk.

The message for the practitioner? When treating a coronary patient, our intervention is no longer merely supportive therapy, but a pillar of their overall systemic health.

Conclusion: Towards integrated management of periodontal and systemic health

This review highlights the role of periodontitis, which affects 35% to 50% of adults, as a true chronic inflammatory hub. Beyond the oral cavity, the pathophysiological mechanisms rely on bacterial translocation, oxidative stress and major immune dysregulation. The study emphasises a shared genetic predisposition with cardiovascular diseases, involving specific loci such as CDKN2B-AS1 (ANRIL), PLG, CAMTA1/VAMP3 and VAMP8, which partly explains the comorbidity observed between these pathologies.

For the practitioner, the clinical relevance is immediate: periodontal treatment must no longer be considered in isolation. The identification of pathogens such as P. gingivalis or A. actinomycetemcomitans in atheromatous plaques confirms that local debridement reduces the overall systemic inflammatory burden. The key take-home message for the practice is that controlling periodontal infection constitutes an essential lever for secondary prevention, requiring increased interdisciplinary collaboration with cardiologists to optimise the systemic prognosis of our patients.

Technical glossary of the study

Dental biofilm: Structured aggregate of microorganisms initiating periodontitis, the development of which involves the formation of an acquired pellicle, bacterial adhesion, maturation and microbial coaggregation.

Osteoclastogenesis: Biological process of osteoclast formation, activated by a host inflammatory cascade in response to the biofilm, leading to alveolar bone resorption.

Bacterial translocation: Mechanism of haematogenous dissemination by which periodontal bacteria or their components enter the systemic circulation, inducing distant pathogenic effects.

Endothelial dysfunction: Alteration of the physiological function of the vascular endothelium, promoted by periodontal inflammation and increasing susceptibility to primary coronary events.

Resolvin E1: Anti-inflammatory lipid mediator used in experimental models to significantly reduce periodontal tissue destruction and arterial plaque formation.

Genetic susceptibility loci: Specific DNA segments, such as CDKN2B-AS1 (ANRIL) and PLG, identified as regulators of aberrant inflammatory responses common to periodontitis and cardiovascular diseases.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all liability regarding the use of this information. This document is not intended for patients or the general public.